Preconception counselling: A five-year experience in a teratology information service

Letters in Drug Design and Discovery

Volumn 7, Issue 5, 2010, Pages 346-352

  de Santis, Marco ^a   Cesari, Elena ^a   de Luca, Carmen ^a   Mappa, Ilenia ^a   Quattrocchi, Tomasella ^a   Visconti, Daniela ^a   Caruso, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chronic diseases; Drugs; Folic acid; Preconception care; Pregnancy; Preventive medicine; Teratology

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTHELMINTIC AGENT; ANTI ACNE AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; FOLIC ACID; GASTROINTESTINAL AGENT; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; SEX HORMONE; UNINDEXED DRUG; VACCINE; VASOACTIVE AGENT;

ARTICLE; DRUG EXPOSURE; DRUG SAFETY; EPILEPSY; EXPERIENCE; FEMALE; HIGH RISK PATIENT; HUMAN; MEDICAL INFORMATION SYSTEM; PATIENT COUNSELING; PREGNANCY; PRENATAL CARE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; TERATOGENESIS; TERATOLOGY;

EID: 77953700635     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010791163442     Document Type: Article

References (36)

1. Boulet, S.L.; Johnson K; Parker C; Posner S.F; Atrash H. A per spective of preconception Health activities in the Unites State. Mater. Child Health J., 2006; 10: S12-S20.
2. Posner, S.F.; Johnson, K.; Parker, C.; Atrash, H.; Biermann, J. The national summit on preconception care: a summary of concepts and recommendations. Mater. Child Health J., 2006, 10, S197-S205.
3. Engeland, A; Bramness, J.G.; Daltveit, A.K.; Rønning, M.; Skurtveit, S.; Furu, K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106000 pregnancies in Norway 2004-2006. Br. J. Clin. Pharmacol., 2008, 65(5), 653-660.
4. Coll, O.; Pisa S.; Palacio, M.; Quintó, L.; Cararach, V. Awareness of the use of folic acid to prevent neural tube defects in a Mediterranean area. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 10, 115(2), 173-177.
5. De Santis, M.; Straface, G.; Carducci, B.; Cavaliere, A.F.; De Santis, L.; Lucchese, A.; Merola, A.M.; Caruso, A. Risk of druginduced congenital defects. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 10, 117(1), 10-9.
6. Shaefer, C.; Hanneman, D.; Meister, R. Post marketing surveillance system for drugs in pregnancy-15 years experience of ENTIS. Reprod. Toxicol., 2005, 20, 331-343.
7. WHO Collaborating Centre for Drug Statistics Methodology http://www.whocc.no/atc_ddd_index/ Accessed March 30, 2009.
8. De Santis, M.; Carducci, B.; Cavaliere, A.F.; De Santis, L.; Straface, G; Caruso, A. Drug-induced congenital defects: strategies to reduce the incidence. Drug Saf., 2001, 24(12), 889-901.
9. Fisher, B.; Rose, N.C.; Carey, J.C. Principles and practice of teratology for the Obstetrician. Clin. Obstet. Gynecol., 2008, 51(1), 106-118.
10. Diav-Citrin, O.; Shechtman, S.; Weinbaum, D.; Avgil, M.; Di Gianantonio, E.; Clementi, M.; Weber-Schoendorfer, C.; Schaefer, C.; Ornoy, A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled; observational study. Br. J. Clin. Pharmacol., 2008, 66(5), 695-705.
11. Hancock, R.L.; Koren, G.; Einarson, A.; Ungar, W. The effectiveness of Teratology Information service (TIS). Repr. Toxicol., 2007, 23, 125-132.
12. US Food and Drug administration http://www.fda.gov (accessed March 30, 2009).
13. Doering, P.L.; Boothby, L.A.; Cheok, M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am. J. Obstet. Gynecol., 2002, 187, 333-339.
14. [No authors listed]. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee Teratology. 1994, 49(6), 446-447.
15. Addis, A.; Sharabi, S.; Bonati, M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf., 2000; 23(3), 245-253.
16. Biermann, J.; Dunlop, A.L.; Brady, C.; Dubin, C.; Brann A.J. Promising practices in preconception care for poor health and pregnancy outcomes. Mater. Child Health J., 2006, 10, S21-S28.
17. Hardy, J.R.; Leaderer, B.P.; Holford, T.R.; Hall, G.C.; Bracken, M.B. Safety of medications prescribed before and during early pregnancy in a cohort of 81;975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf., 2006, 15(8), 555-64.
18. Andrade, S.E.; Gurwitz, J.H.; Davis, R.L.; Chan, K.A.; Finkelstein, J.A.; Fortman, K.; McPhillips, H.; Raebel, M.A.; Roblin, D.; Smith, D.H.; Yood, M.U.; Morse, A.N.; Platt, R. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol., 2004, 191(2), 398-407.
19. Malm, H.; Martikainen, J.; Klaukka, T.; Neuvonen, P.J. Prescription of hazardous drugs during pregnancy. Drug Saf., 2004, 27(12), 899-908.
20. Bakker, M.K.; Jentink, J.; Vroom, F.; Van Den Berg, P.B.; De Walle, H.E.; De Jong-Van Den Berg, L.T. Drug prescription patterns before; during and after pregnancy for chronic; occasional and pregnancy-related drugs in the Netherlands. BJOG, 2006, 113(5), 559-568.
21. Schwarz, E.B.; Maselli, J.; Norton, M.; Gonzales, R. Prescription of teratogenic medications in United States ambulatory practices. Am. J. Med., 2005, 118(11), 1240-1249.
22. Bakker, M.K.; Kölling, P.; van den Berg, P.B.; de Walle, H.E.; de Jong van den Berg, L.T. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade; a population based cohort study from the Netherlands. Br. J. Clin. Pharmacol., 2008, 65(4), 600-606.
23. Andrade, S.E.; Raebel, M.A.; Brown, J.; Lane, K.; Livingston, J.; Boudreau, D.; Rolnick, S.J.; Roblin, D.; Smith, D.H.; Willy, M.E.; Staffa, J.A.; Platt, R. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol., 2008, 198(2), 194.
24. Einarson, T.R.; Einarson, A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf., 2005, 14(12), 823-827.
25. Chambers, C.D.; Hernandez-Diaz, S.; Van Marter, L.J.; Werler, M.M.; Louik, C.; Jones, K.L.; Mitchell, A.A. Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med., 2006, 354(6),579-587.
26. [No authors listed]. ACOG committee on obstetric practice. Committee opinion no 354: treatment with selective serotonin reuptake inhibitors during pregnancy. Obst. Gyn., 2006, 108(6), 1601-1603.
27. Louik, C; Lin, A.E; Werler, M.M.; Hernandez-Diaz, S.; Mitchell, A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med., 2007, 356, 2675-2783.
28. Brent, R.L. Teratology in the 20th century environmental causes of congenital malformations in humans and how they were established. Neurotoxicol. Teratol., 2004, 26(1), 1-12.
29. Atrash, H.; Johnson, K.; Adams, M.; Cordero, J.F.; Howse, J. Preconception care for improving perinatal outcome: the time to act. Mater. Child Health J., 2006, 10, S3-S11.
30. Cox, M.; Whittle, M.J.; Byrne, A. Prepregnancy counselling: experience from 1075 cases. Br. J. Obst. Gynecol., 1992, 99, 873-876.
31. Bonari, L.; Koren, G.; Einarson, T.R.; Jasper, J.D.; Taddio, A.; Einarson, A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Womens Ment. Health., 2005, 8(4), 214-220.
32. Clark, N.A.; Fisk, N.M. Minimal compliance with the department of health recommendation for routine folate prophylaxis to prevent neural tube defects. Br. J. Obst. Gynechol., 1994, 101, 709-710.
33. [No authors listed]. Centers of Disease Control: Knowledge and use of folic acid by women of childbearing age-USA. Morb. Mortal. Wkly. Rep., 1997, 46(31), 721-723.
34. [No authors listed]. Centres for Disease Control and Prevention. Knowledge and use of folic acid by women of childbearing age: Michigan 1998. Morbidity and Mortality Weekly Report, 2001, 50, 185-189.
35. Stepanuk, K.M.; Tolosa, J.E.; Lewis, D.; Myers, V.; Royds, C.; Sabogal, J.C.; Librizzi, R. Folic acid supplementation use among women who contact a teratology information service Am. J. Obst. Gyn., 2002, 187(4), 964-947.
36. [No authors listed]. Commission on Genetics; Pregnancy; and the Child; International League Against Epilepsy. Guidelines for the care of epileptic women of childbearing age. Epilepsia, 1989, 30,409-410.